Publications - 'F'
Publications 651 - 675 de 1212
| Titre | DOI |
|---|---|
|
Focal cryoablation: a treatment option for unilateral low-risk prostate cancer M. Durand; E. Barret; M. Galiano; F. Rozet; R. Sanchez-Salas; Y. Ahallal; P. Macek; J.M. Gaya; J. Cerruti; H. Devilliers; J. Loeffler; J. Amiel; G. Vallancien; X. Cathelineau 2014 |
10.1111/bju.12370 |
|
Focal Nodal SBRT or Elective Nodal Protracted Salvage Radiation Therapy for Prostate Cancer Patients With a Choline PET-CT Positive Nodal Relapse G. Crehange; P. Maingon; A. Cueff; G. Truc; K. Peignaux; F. Mazoyer; N. Vulquin; M. Quivrin; S. Naudy; E. Martin 2015 |
10.1016/j.ijrobp.2015.07.1159 |
|
Focal or whole gland salvage prostate brachytherapy with iodine seeds with or without a rectal spacer for a post EBRT local failure: How best to spare the rectum? V. Guimas; M. Quivrin; A. Bertaut; E. Martin; F. Mazoyer; P. Maingon; L. Cormier; G. Crehange 2016 |
10.1200/jco.2016.34.2_suppl.e636 |
|
Focal or whole-gland salvage prostate brachytherapy with iodine seeds with or without a rectal spacer for postradiotherapy local failure: How best to spare the rectum? V. Guimas; M. Quivrin; A. Bertaut; E. Martin; D. Chambade; P. Maingon; F. Mazoyer; L. Cormier; G. Crehange 2016 |
10.1016/j.brachy.2016.03.014 |
|
Focus Issue on Unique Materials, Techniques, and Environments Y. Wouters; B.A. Pint; D. Monceau; M. Vilasi; S. Chevalier; L. Latu-Romain; C. Desgranges 2021 |
10.1007/s11085-021-10081-4 |
|
Focus on an unusual rise in pancreatic cancer incidence in France A.M. Bouvier; Z. Uhry; V. Jooste; A. Drouillard; L. Remontet; G. Launoy; N. Leone; F.Network Ca FRA 2017 |
10.1093/ije/dyx088 |
|
Focus on stereotactic radiotherapy: A new way to treat severe ventricular arrhythmias? F. Sacher; E. Gandjbakhch; P. Maury; C. Jenny; J. Khalifa; S. Boveda; P. Defaye; D. Gras; D. Klug; G. Laurent; N. Lellouche; J. Mansourati; E. Marijon; O. Piot; J. Taieb; H. Cochet; P. Maingon; E. Pruvot; L. Fauchier; F.Soc Cardiology 2021 |
10.1016/j.acvd.2020.11.003 |
|
Focus on the Odon Device (TM): Technical improvements, mechanical principles and progress of the clinical research program N. Mottet; A. Bourtembourg; A. Eckman-Lacroix; O. Forner; C. Mougey; J.P. Metz; R. Ramanah; D. Riethmuller 2020 |
10.1016/j.gofs.2020.03.011 |
|
Focused linearly-polarized-light scattering from a silver nanowire: Experimental characterization of the optical spin-Hall effect D. Paul; D.K. Sharma; G.V.Pavan Kumar 2021 |
10.1103/PhysRevA.103.013520 |
|
FOLFIRI plus bevacizumab as a second-line therapy for metastatic intrahepatic cholangiocarcinoma J.F. Guion-Dusserre; V. Lorgis; J. Vincent; L. Bengrine; F. Ghiringhelli 2015 |
10.3748/wjg.v21.i7.2096 |
|
FOLFIRI plus bevacizumab induction chemotherapy followed by bevacizumab or observation in metastatic colorectal cancer, a phase III trial (PRODIGE 9-FFCD 0802) T. Aparicio; B. Linot; K. Le Malicot; O. Bouche; V. Boige; E. Francois; F. Ghiringhelli; J.L. Legoux; M. Ben Abdelghani; J.M. Phelip; R. Faroux; L. Dahan; J. Taieb; L. Bedenne 2015 |
10.1016/j.dld.2015.01.146 |
|
FOLFIRI3-aflibercept as second- or later-line therapy in patients with metastatic colorectal cancer C. Carola; F. Ghiringhelli; S. Kim; T. Andre; J. Barlet; L. Bengrine; H. Marijon; M.Line Garcia; C. Borg; L. Dainese; N. Steuer; A.K. Larsen; A. de Gramont; B. Chibaudel 2018 |
10.1200/JCO.2018.36.4_suppl.817 |
|
FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer C. Carola; F. Ghiringhelli; S. Kim; T. Andre; J. Barlet; L. Bengrine-Lefevre; H. Marijon; M.L. Garcia-Larnicol; C. Borg; L. Dainese; N. Steuer; H. Richa; M. Benetkiewicz; A.K. Larsen; A. de Gramont; B. Chibaudel 2018 |
10.5306/wjco.v9.i5.110 |
|
FOLFIRINEC: a randomized phase II trial of mFOLFIRINOX vs platinum-etoposide for metastatic neuroendocrine carcinoma of gastroenteropancreatic or unknown origin J. Hadoux; P. Afchain; T. Walter; D. Tougeron; V. Hautefeuille; C. Monterymard; V. Lorgis; F. Thuillier; E. Baudin; J.Yves Scoazec; C. Lepage; R. Desgrippes 2021 |
10.1016/j.dld.2021.04.016 |
|
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases (RCSM): Final results of the FFCD 1102 phase II trial J.B. Bachet; O. Lucidarme; C.B. Levache; E. Maillard; J.L. Raoul; T. Lecomte; C. Desauw; F. Brocard; S. Pernot; G. Breysacher; J.P. Lagasse; F. Di Fiore; P.L. Etienne; O. Dupuis; A. Aleba; C. Lepage; J. Taieb 2017 |
|
|
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial J.B. Bachet; O. Lucidarme; C.B. Levache; E. Barbier; J.L. Raoul; T. Lecomte; C. Desauw; F. Brocard; S. Pernot; G. Breysacher; J.P. Lagasse; F. Di Fiore; P.L. Etienne; O.J.M. Dupuis; A. Aleba; C. Lepage; J. Taieb; F.F.C.D.1102 Investigators 2018 |
10.1016/j.ejca.2018.09.006 |
|
FOLFIRINOX Bevacizumab Is a Promising Therapy for Chemorefractory Metastatic Colorectal Cancer M. Chaix; J. Vincent; V. Lorgis; F. Ghiringhelli 2014 |
10.1159/000361031 |
|
FOLFIRINOX combined to targeted therapy according RAS status for colorectal cancer patients with liver metastases initially non-resectable: A phase II randomized Study-Prodige 14-ACCORD 21 (METHEP-2), a unicancer GI trial. M. Ychou; M. Rivoire; S. Thezenas; R. Guimbaud; F. Ghiringhelli; A. Mercier-Blas; L. Mineur; E. Francois; F. Khemissa; D. Moussata; Y. Becouarn; P. Houyau; T. Aparicio; R. Adam; M.P. Galais; F. Audemar; E. Assenat; T. Stanbury; O. Bouche 2016 |
10.1200/JCO.2016.34.15_suppl.3512 |
|
FOLFIRINOX de-escalation in advanced pancreatic cancer (aPC): A multicenter real-life study. H. Chevalier; A. Vienot; A. Lievre; J. Edeline; F.El Hajbi; C. Peugniez; D. Vernerey; A. Meurisse; P. Hammel; C. Neuzillet; C. Borg; A. Turpin 2020 |
|
|
FOLFIRINOX de-escalation in advanced pancreatic cancer (aPC): A multicenter real-life study. H. Chevalier; A. Vienot; A. Lievre; J. Edeline; F.El Hajbi; C. Peugniez; D. Vernerey; A. Meurisse; P. Hammel; C. Neuzillet; C. Borg; A. Turpin 2020 |
|
|
FOLFIRINOX De-Escalationin Advanced Pancreatic Cancer: A MulticenterReal-LifeStudy H. Chevalier; A. Vienot; A. Lievre; J. Edeline; F.El Hajbi; C. Peugniez; D. Vernerey; A. Meurisse; P. Hammel; C. Neuzillet; C. Borg; A. Turpin 2020 |
10.1634/theoncologist.2020-0577 |
|
Folfirinox in elderly patients with pancreatic or colorectal cancer-tolerance and efficacy J.F. Guion-Dusserre; A. Bertaut; F. Ghiringhelli; J. Vincent; V. Quipourt; S. Marilier; Z. Tharin; L. Bengrine-Lefevre 2016 |
10.3748/wjg.v22.i42.9378 |
|
FOLFIRINOX in locally advanced (LA) and borderline resectable (BR) pancreatic adenocarcinoma: Update of the AGEO cohort E. Auclin; L. Marthey; L. Mas; E. Francois; S. Cunha; J.B. Bachet; D. Tougeron; A. Vienot; T. Lecomte; V. Hautefeuille; J. Forestier; M. Collins; R. Abdallah; R. Coriat; A.L. Pointet; F. Leroy; F. Ksontini; N. Williet; J. Taieb 2019 |
|
|
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer T. Conroy; P. Hammel; M. Hebbar; M. Ben Abdelghani; A.C. Wei; J.L. Raoul; L. Chone; E. Francois; P. Artru; J.J. Biagi; T. Lecomte; E. Assenat; R. Faroux; M. Ychou; J. Volet; A. Sauvanet; G. Breysacher; F. Di Fiore; C. Cripps; P. Kavan; P. Texereau; K. Bouhier-Leporrier; F. Khemissa-Akouz; J.L. Legoux; B. Juzyna; S. Gourgou; C.J. O'Callaghan; C. Jouffroy-Zeller; P. Rat; D. Malka; F. Castan; J.B. Bachet; C.Canc Trial Grp; U.G.I.P.R.O.D.I.G.E. Grp 2018 |
10.1056/NEJMoa1809775 |
|
FOLFIRINOX plus cetuximab (CET) or bevacizumab (BEV) in patients (pts) with initially unresectable colorectal liver metastases (CRLM) with BRAF mutated (mut) tumors: A subgroup analysis of the UNICANCER PRODIGE 14-ACCORD 21 (METHEP2) trial. E. Lopez-Crapez; A. Adenis; S. Thezenas; E. Assenat; E. Francois; R. Guimbaud; M. Chauvenet; F. Khemissa; F. Audemar; E. Suc; M. Rivoire; F. Ghiringhelli; A. Mercier-Blas; L. Mineur; Y. Becouarn; P. Houyau; T. Stanbury; C. Jouffroy-Zeller; O. Bouche; M. Ychou 2018 |
10.1200/JCO.2018.36.15_suppl.3548 |